Orient Gene
Established in 2005
In 2005
Zhejiang Orient Gene Biotech Co., Ltd. was registered and established.
In 2009
Zhejiang Provincial Postdoctoral Research Station was established.
In 2013
The Huzhou Academician Expert Workstation was established and recognized as a National High-tech Enterprise.
In 2014
Passed the field inspection of US FDA with zero defects.
In 2015
Hangzhou D&W was established to enter the field of molecular diagnosis.
In 2016
The company accelerated the globalization and the business layout of the whole industrial chain, set up Healgen and Shanghai Douglas as the international sales platforms
In 2016
Canada Healstone and Qingdao Handsen as the R&D platforms of antigens and antibodies
In 2016
Nanjing Healvity as a diagnostic instrument platform
In 2016
Hangzhou ShineDo as a liquid biochip platform
In 2017
The company completed the joint-stock company restructuring. This year, the company has achieved an operating income of more than 200 million yuan, and at the same time, has established Hangzhou Wanzijian as a domestic sales platform.
In 2018
The company’s malaria detection kit was selected and funded by the Bill & Melinda Gates Foundation for pre-certification by the World Health Organization.
In 2019
The company cooperated with Shanghai Jiaotong University on liquid biochip related technologies; meanwhile, the company has been deeply involved in the international market, with customers in more than 120 countries and regions around the world.
In 2020
The IPO stock of the company was listed on the STAR Market at Shanghai Stock Exchange
In 2020
The company successfully developed the COVID-19 antibody/nucleic acid/antigen detection reagent, which helped the global epidemic situation
In 2020
In the first half of the year, the company achieved an operating income of 828 million yuan, achieving a major breakthrough in the bottleneck of development scale.